Patent intelligence · US
US 10722581
Phonophoretic cannabidiol composition and transdermal delivery system
Phonophoretic cannabidiol composition and transdermal delivery system
Patent details — US 10722581
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 28, 2020
- Expiration
- Jul 23, 2040
- Applicant
- Essential Green Goodness LLC
- Claims
- 9
- CPC classes
- A61K, A61K31/05, A61K31/658, A61K41/0047
Quick answer
US 10722581 (Phonophoretic cannabidiol composition and transdermal delivery system) is held by Essential Green Goodness LLC. Status: granted. Granted Jul 28, 2020. Expires Jul 23, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Essential Green Goodness LLC
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/05, A61K31/658, A61K41/0047
More from Essential Green Goodness LLC
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 10722581?
US 10722581 (Phonophoretic cannabidiol composition and transdermal delivery system) is held by Essential Green Goodness LLC. Status: granted. Granted Jul 28, 2020. Expires Jul 23, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10722581?
Essential Green Goodness LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 10722581 expire?
Our index shows an expiration date of Jul 23, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.